Anti-AML in vivo activity required NK cell persistence, which was achieved using alpharetroviral vectors to engineer NK cells to constitutively co-express hIL-15 in addition to the anti-CD123-CAR. The gene discussed is IL3RA; the disease is acute myeloid leukemia.